Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

IONS

Live52w high -10.5%

Core line items from IONS's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Entity: IONIS PHARMACEUTICALS, INC.·Source: SEC EDGAR companyfacts

Metric	Annual 2025 2025-12-31	Annual 2024 2024-12-31	Annual 2023 2023-12-31	Annual 2022 2022-12-31
Revenue	$943.71M	$705.14M	$787.65M	$587.37M
Operating Income	$-381.68M	$-475.08M	$-353.73M	$-410.19M
Net Income	$-381.39M	$-453.90M	$-366.29M	$-269.72M
EPS (Diluted)	$-2.38	$-3.04	$-2.56	$-1.90
Total Assets	$3.52B	$3.00B	$2.99B	$2.53B
Total Liabilities	$3.03B	$2.42B	$2.60B	$1.96B
Cash & Equivalents	$372.26M	$242.08M	$399.27M	$276.47M
Free Cash Flow OCF − CapEx	$-320.03M	$-546.23M	$-331.32M	$-290.09M
Shares Outstanding	163.30M	157.91M	144.34M	142.06M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data.

Core line items from IONS's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w high -10.5%

Entity: IONIS PHARMACEUTICALS, INC.·Source: SEC EDGAR companyfacts

Metric	Annual 2025 2025-12-31	Annual 2024 2024-12-31	Annual 2023 2023-12-31	Annual 2022 2022-12-31
Revenue	$943.71M	$705.14M	$787.65M	$587.37M
Operating Income	$-381.68M	$-475.08M	$-353.73M	$-410.19M
Net Income	$-381.39M	$-453.90M	$-366.29M	$-269.72M
EPS (Diluted)	$-2.38	$-3.04	$-2.56	$-1.90
Total Assets	$3.52B	$3.00B	$2.99B	$2.53B
Total Liabilities	$3.03B	$2.42B	$2.60B	$1.96B
Cash & Equivalents	$372.26M	$242.08M	$399.27M	$276.47M
Free Cash Flow OCF − CapEx	$-320.03M	$-546.23M	$-331.32M	$-290.09M
Shares Outstanding	163.30M	157.91M	144.34M	142.06M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data.